BRPI0915513B8 - compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes - Google Patents

compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes

Info

Publication number
BRPI0915513B8
BRPI0915513B8 BRPI0915513A BRPI0915513A BRPI0915513B8 BR PI0915513 B8 BRPI0915513 B8 BR PI0915513B8 BR PI0915513 A BRPI0915513 A BR PI0915513A BR PI0915513 A BRPI0915513 A BR PI0915513A BR PI0915513 B8 BRPI0915513 B8 BR PI0915513B8
Authority
BR
Brazil
Prior art keywords
compounds
preparation
carboxylic acid
pharmaceutical compositions
substituted phenoxy
Prior art date
Application number
BRPI0915513A
Other languages
English (en)
Inventor
Cook Adam
P Corrette Christopher
t clark Christopher
Kim Ganghyeok
A Doherty George
W Hunt Kevin
E Burgess Laurence
Kirk Delisle Robert
Romoff Todd
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BRPI0915513A2 publication Critical patent/BRPI0915513A2/pt
Publication of BRPI0915513B1 publication Critical patent/BRPI0915513B1/pt
Publication of BRPI0915513B8 publication Critical patent/BRPI0915513B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

compostos derivados de ácido fenóxicromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes. a presente invenção refere-se a compostos da fórmula (i): em que a1, a2, w, l, g, r7a, r7b, r8 e r10 possuem os significados fornecidos no relatório descritivo e são moduladores do receptor dp2, úteis no tratamento de doenças imunológicas.
BRPI0915513A 2008-06-25 2009-06-24 compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes BRPI0915513B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7561508P 2008-06-25 2008-06-25
PCT/US2009/048499 WO2009158426A1 (en) 2008-06-25 2009-06-24 6-substituted phenoxychroman carboxylic acid derivatives

Publications (3)

Publication Number Publication Date
BRPI0915513A2 BRPI0915513A2 (pt) 2016-01-26
BRPI0915513B1 BRPI0915513B1 (pt) 2019-11-19
BRPI0915513B8 true BRPI0915513B8 (pt) 2021-05-25

Family

ID=40996727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915513A BRPI0915513B8 (pt) 2008-06-25 2009-06-24 compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes

Country Status (32)

Country Link
US (4) US8569522B2 (pt)
EP (3) EP2307397B1 (pt)
JP (2) JP5753780B2 (pt)
KR (1) KR101728175B1 (pt)
CN (2) CN103450138B (pt)
AR (1) AR072301A1 (pt)
AU (1) AU2009262274B2 (pt)
BR (1) BRPI0915513B8 (pt)
CA (1) CA2729217C (pt)
CL (1) CL2010001528A1 (pt)
CO (1) CO6362002A2 (pt)
CR (1) CR20110037A (pt)
CY (1) CY1115650T1 (pt)
DK (1) DK2307397T3 (pt)
ES (2) ES2524314T3 (pt)
HR (1) HRP20140988T1 (pt)
IL (2) IL210198A (pt)
MX (1) MX2011000173A (pt)
MY (2) MY161425A (pt)
NZ (1) NZ590437A (pt)
PH (1) PH12014500079B1 (pt)
PL (1) PL2307397T3 (pt)
PT (1) PT2307397E (pt)
RS (1) RS53665B1 (pt)
RU (1) RU2507200C2 (pt)
SG (2) SG2014013528A (pt)
SI (1) SI2307397T1 (pt)
TW (2) TWI476186B (pt)
UA (1) UA104867C2 (pt)
UY (1) UY31938A (pt)
WO (1) WO2009158426A1 (pt)
ZA (1) ZA201100604B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450138B (zh) 2008-06-25 2015-04-08 阵列生物制药公司 制备6-取代的苯氧基色满羧酸衍生物的中间体
CN102325767B (zh) * 2008-12-22 2014-05-14 阵列生物制药公司 7-苯氧基色满羧酸衍生物
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI654180B (zh) 2012-06-29 2019-03-21 美商艾佛艾姆希公司 殺真菌之雜環羧醯胺
TW201507722A (zh) * 2013-04-30 2015-03-01 Bayer Cropscience Ag 做為殺線蟲劑及殺體內寄生蟲劑的ｎ－（２－鹵素－２－苯乙基）－羧醯胺類
WO2015126750A1 (en) 2014-02-19 2015-08-27 Array Biopharma Inc. BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO TREATMENT WITH A CRTh2 INHIBITOR
CN111057003A (zh) * 2019-12-06 2020-04-24 广安凯特制药有限公司 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法
SE2151519A1 (en) * 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
CN114181039A (zh) * 2021-12-23 2022-03-15 凯美克(上海)医药科技有限公司 一种4,4-二苯基-3-丁烯-1-醇的合成方法
WO2025046475A1 (ko) * 2023-08-29 2025-03-06 제이더블유중외제약 주식회사 아토피성 피부염 치료용 헤테로환형 유도체

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5006550A (en) * 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5952326A (en) 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
HRP20010861A2 (en) 1999-05-21 2003-04-30 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
WO2002022556A1 (en) * 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
PL377314A1 (pl) * 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
CA2599352A1 (en) * 2005-02-25 2006-09-08 Eli Lilly And Company Novel lipoxygenase inhibitors
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
AU2007286829B2 (en) * 2006-08-21 2013-05-02 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives
WO2008054675A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
CN103450138B (zh) * 2008-06-25 2015-04-08 阵列生物制药公司 制备6-取代的苯氧基色满羧酸衍生物的中间体
CN102325767B (zh) * 2008-12-22 2014-05-14 阵列生物制药公司 7-苯氧基色满羧酸衍生物

Also Published As

Publication number Publication date
CY1115650T1 (el) 2017-01-04
HK1155735A1 (en) 2012-05-25
RU2507200C2 (ru) 2014-02-20
IL210198A0 (en) 2011-03-31
TWI476186B (zh) 2015-03-11
TWI436990B (zh) 2014-05-11
MY161425A (en) 2017-04-14
NZ590437A (en) 2012-07-27
KR101728175B1 (ko) 2017-04-18
WO2009158426A1 (en) 2009-12-30
US8569522B2 (en) 2013-10-29
ES2582161T3 (es) 2016-09-09
HRP20140988T1 (hr) 2014-12-05
PT2307397E (pt) 2014-10-29
AR072301A1 (es) 2010-08-18
UY31938A (es) 2011-01-31
CN103450138B (zh) 2015-04-08
ZA201100604B (en) 2015-08-26
DK2307397T3 (da) 2014-11-03
CN102131794B (zh) 2013-09-25
CL2010001528A1 (es) 2011-07-01
IL210198A (en) 2015-10-29
US8716498B2 (en) 2014-05-06
US20110105463A1 (en) 2011-05-05
EP2307397A1 (en) 2011-04-13
US20140221342A1 (en) 2014-08-07
JP2011526290A (ja) 2011-10-06
CA2729217A1 (en) 2009-12-30
CN103450138A (zh) 2013-12-18
EP2307397B1 (en) 2014-08-20
SI2307397T1 (sl) 2014-11-28
MY185134A (en) 2021-04-30
JP2014122241A (ja) 2014-07-03
KR20110027798A (ko) 2011-03-16
SG2014013528A (en) 2014-07-30
CN102131794A (zh) 2011-07-20
TW201427965A (zh) 2014-07-16
SG2014013544A (en) 2014-07-30
EP3144303A1 (en) 2017-03-22
EP3144303B1 (en) 2018-09-26
AU2009262274B2 (en) 2013-08-01
US9096567B2 (en) 2015-08-04
TW201022222A (en) 2010-06-16
BRPI0915513A2 (pt) 2016-01-26
CR20110037A (es) 2011-03-14
JP5753780B2 (ja) 2015-07-22
MX2011000173A (es) 2011-06-20
PL2307397T3 (pl) 2015-02-27
PH12014500079A1 (en) 2015-02-09
UA104867C2 (uk) 2014-03-25
RS53665B1 (sr) 2015-04-30
AU2009262274A1 (en) 2009-12-30
CO6362002A2 (es) 2012-01-20
PH12014500079B1 (en) 2015-02-09
IL241754A0 (en) 2015-11-30
EP2826774A1 (en) 2015-01-21
US20140005418A1 (en) 2014-01-02
US9556139B2 (en) 2017-01-31
BRPI0915513B1 (pt) 2019-11-19
EP2826774B1 (en) 2016-05-25
US20150232442A1 (en) 2015-08-20
IL241754A (en) 2017-02-28
RU2011102595A (ru) 2012-07-27
ES2524314T3 (es) 2014-12-05
CA2729217C (en) 2016-09-06

Similar Documents

Publication Publication Date Title
BRPI0915513B8 (pt) compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes
BR112012009214A2 (pt) compostos
BRPI0707302B8 (pt) compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
MX2010001535A (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa.
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2676 DE 19-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.